49 related articles for article (PubMed ID: 20497915)
1. Ten remarkable years.
Sledge GW
Clin Breast Cancer; 2010 Jun; 10(3):178. PubMed ID: 20497915
[No Abstract] [Full Text] [Related]
2. Where to with HER2?
Sledge GW
Clin Breast Cancer; 2010 Feb; 10(1):18. PubMed ID: 20133253
[No Abstract] [Full Text] [Related]
3. HER2011: the changing face of HER2-positive breast cancer.
Sledge GW
Clin Breast Cancer; 2011 Mar; 11(1):9. PubMed ID: 21421515
[No Abstract] [Full Text] [Related]
4. TEACH: Tykerb evaluation after chemotherapy.
Moy B; Goss PE
Clin Breast Cancer; 2007 Feb; 7(6):489-92. PubMed ID: 17386127
[No Abstract] [Full Text] [Related]
5. Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?
Chandarlapaty S; Modi S
J Clin Oncol; 2011 Aug; 29(23):3111-3. PubMed ID: 21730267
[No Abstract] [Full Text] [Related]
6. [Advances in research on treatment of breast cancer with lapatinib].
Ma CD; Shen KW; Shen ZZ
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):321-4. PubMed ID: 18953827
[No Abstract] [Full Text] [Related]
7. [Sensitivity of chemotherapy depending on hormone status in breast cancer].
Ito Y
Nihon Rinsho; 2007 Jun; 65 Suppl 6():568-71. PubMed ID: 17679212
[No Abstract] [Full Text] [Related]
8. [Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].
Zhang B
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):241-4. PubMed ID: 21575491
[No Abstract] [Full Text] [Related]
9. Triple-negative breast cancer.
Oncology (Williston Park); 2010 Oct; 24(10 Suppl):40a. PubMed ID: 21275325
[No Abstract] [Full Text] [Related]
10. Coming of age: breast cancer in seniors.
Muss HB
Oncologist; 2011; 16 Suppl 1():79-87. PubMed ID: 21278444
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
Venkitaraman R
Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
[TBL] [Abstract][Full Text] [Related]
12. [Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the financing of Tyverb (lapatinib) based on individual discretionary compassionate care].
Pikó B;
Magy Onkol; 2009 Mar; 53(1):77-9. PubMed ID: 19318330
[No Abstract] [Full Text] [Related]
13. Closing in on a cure.
Healy B
US News World Rep; 2006 Oct; 141(15):67. PubMed ID: 17432437
[No Abstract] [Full Text] [Related]
14. Adjuvant chemotherapy for early-stage breast cancer.
McArthur HL; Hudis CA
Hematol Oncol Clin North Am; 2007 Apr; 21(2):207-22. PubMed ID: 17512445
[TBL] [Abstract][Full Text] [Related]
15. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
Glück S; Arteaga CL; Osborne CK
Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
[TBL] [Abstract][Full Text] [Related]
16. Biological therapy of breast cancer: recent clinical applications.
Baar J
Curr Opin Investig Drugs; 2007 Dec; 8(12):987-95. PubMed ID: 18058569
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy is not for everyone.
Henderson IC
Breast Cancer Res Treat; 2010 Aug; 123(1):159-62. PubMed ID: 20549338
[No Abstract] [Full Text] [Related]
18. Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options.
Voduc D; Nielsen TO
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S171-8. PubMed ID: 19158038
[TBL] [Abstract][Full Text] [Related]
19. Search for new treatments intensifies for triple-negative breast cancer.
Brower V
J Natl Cancer Inst; 2009 Nov; 101(22):1536-7. PubMed ID: 19880812
[No Abstract] [Full Text] [Related]
20. Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer.
Burrell RA; Juul N; Johnston SR; Reis-Filho JS; Szallasi Z; Swanton C
J Cell Biochem; 2010 Nov; 111(4):782-90. PubMed ID: 20665662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
